- Trials with a EudraCT protocol (42)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
42 result(s) found for: Meta analysis.
Displaying page 1 of 3.
EudraCT Number: 2020-000595-37 | Sponsor Protocol Number: 1111111 | Start Date*: 2020-12-02 |
Sponsor Name:Fakultní nemocnice v Motole | ||
Full Title: Pharmacokinetics and pharmacodynamics of levobupivacaine during continuous caudal epidural analgesia in newborns | ||
Medical condition: The primary aim of study is to determine PK and PD of levobupivacaine in newborns (premature included). And discover or decline of LA cumulation. The secondary aim of the study is to obtain enough ... | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003138-18 | Sponsor Protocol Number: UCC-Strider | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:University College Cork | |||||||||||||
Full Title: STRIDER Ireland: A Randomised Controlled Trial of Sildenafil Therapy In Dismal Prognosis Early‐Onset Intrauterine Growth Restriction | |||||||||||||
Medical condition: Severe early - onset Intrauterine Growth Restriction (IUGR), (also referred to as Fetal growth restriction) diagnosed between 22+0 and 29+6 gestational age. IUGR is defined as an estimated fetal we... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001099-21 | Sponsor Protocol Number: 2010-04-23 | Start Date*: 2011-05-19 |
Sponsor Name:Population Health Research Institute | ||
Full Title: SIRS Steroids In caRdiac Surgery Trial | ||
Medical condition: From available evidence, corticosteroids attenuate the inflammatory response to CPB which is felt to contribute to morbidity and mortality in cardiac surgery patients. The meta-analysis of the lite... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003130-27 | Sponsor Protocol Number: 2015/2294 | Start Date*: 2017-05-15 | |||||||||||
Sponsor Name:Gustave Roussy | |||||||||||||
Full Title: An international multicenter phase II randomized trial evaluating and comparing two intensification treatment strategies for metastatic neuroblastoma patients with a poor response to induction chem... | |||||||||||||
Medical condition: Very High Risk neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) IT (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) NL (Completed) AT (Prematurely Ended) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001093-55 | Sponsor Protocol Number: NL77315.078.21 | Start Date*: 2022-10-03 |
Sponsor Name:Erasmus Medical center | ||
Full Title: COATS study: genetic Clopidogrel response testing to finetune the antithrombotic regimen in (D)OAC Treated patients undergoing PCI | ||
Medical condition: Patients on oral anticoagulation drugs who undergo a percutaneous coronary intervention (PCI) temporarily and treatment with concomitant antiplatelet therapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001501-24 | Sponsor Protocol Number: IRST100.47 | Start Date*: 2020-04-28 | |||||||||||
Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS | |||||||||||||
Full Title: PROTECT: A randomized study with Hydroxychloroquine versus observational support for prevention or early phase treatment of Coronavirus disease (COVID-19). | |||||||||||||
Medical condition: Group 1: SARS-CoV-2-exposed subjects, as household members/contacts of COVID-19 patients Group 2: Patients with COVID-19 asymptomatic or paucisymptomatic in home situation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005157-24 | Sponsor Protocol Number: 75688 | Start Date*: 2021-09-21 | |||||||||||
Sponsor Name:UMC Utrecht | |||||||||||||
Full Title: [18F]mFBG PET-CT imaging of pheochromocytoma | |||||||||||||
Medical condition: Pheochromocytoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004386-15 | Sponsor Protocol Number: MBG308 | Start Date*: Information not available in EudraCT |
Sponsor Name:GE Healthcare Limited and its affiliates | ||
Full Title: An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma | ||
Medical condition: Phaeochromocytoma and Neuroblastoma | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) GB (Completed) IT (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003872-37 | Sponsor Protocol Number: S63142 | Start Date*: 2020-01-28 |
Sponsor Name:University Hospitals Leuven | ||
Full Title: 18F-MFBG PET imaging of the norepinephrine transporter in neural crest and neuroendocrine tumors: a phase I PET/CT study | ||
Medical condition: Neural crest tumors and neuroendocrine tumors | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-000735-80 | Sponsor Protocol Number: 2010-382 | Start Date*: 2011-05-16 |
Sponsor Name:Lene Drasbek Huusom | ||
Full Title: Administration of antenatal magnesium sulphate for prevention of cerebral palsy in preterm infants (MASP-STUDY) | ||
Medical condition: Moderate to severe cerebral palsy | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002221-11 | Sponsor Protocol Number: RHMCHI0811 | Start Date*: 2017-09-28 | |||||||||||
Sponsor Name:University Hospital Southampton NHS Foundation Trust | |||||||||||||
Full Title: A Phase I study of 131-1 mIBG followed by Nivolumab and Dinutuximab beta in children with relapsed/refractory neuroblastoma | |||||||||||||
Medical condition: Neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000752-41 | Sponsor Protocol Number: E7050-701 | Start Date*: 2011-10-31 | |||||||||||
Sponsor Name:Eisai Inc. | |||||||||||||
Full Title: An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Sorafenib versus Sorafenib Alone as First Line Therapy in Patients with Hepatocellular Carcinoma | |||||||||||||
Medical condition: Hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) BE (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005766-34 | Sponsor Protocol Number: ABI-H0731-204 | Start Date*: 2021-07-22 | |||||||||||
Sponsor Name:Assembly Biosciences, Inc. | |||||||||||||
Full Title: A Randomized Phase 2a, Multicenter, Open-Label, Multiple-Cohort Study Evaluating Regimens Containing Vebicorvir in Subjects with Chronic Hepatitis B Virus Infection | |||||||||||||
Medical condition: Chronic Hepatitis B Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001760-19 | Sponsor Protocol Number: THR-1442-C-476 | Start Date*: 2016-01-07 | |||||||||||
Sponsor Name:Theracos Sub, LLC | |||||||||||||
Full Title: A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events | |||||||||||||
Medical condition: Type II diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) PL (Completed) DK (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000935-15 | Sponsor Protocol Number: PRODIGE70-CIRCULATE | Start Date*: 2019-09-10 |
Sponsor Name:Centre Hospitalier Universitaire (CHU) de Dijon | ||
Full Title: CIRCULATE- CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II | ||
Medical condition: stage II colon cancer, after tumour resection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2008-001168-35 | Sponsor Protocol Number: A4021018 | Start Date*: 2008-07-09 | |||||||||||
Sponsor Name:PFIZER, S.A. | |||||||||||||
Full Title: ENSAYO ALEATORIZADO, ABIERTO, EN FASE 3 DE ERLOTINIB SOLO O EN COMBINACION CON CP-751,871 EN PACIENTES CON CANCER DE PULMON NO MICROCITICO AVANZADO DE HISTOLOGIA NO ADENOCARCINOMATOSA. | |||||||||||||
Medical condition: CPNM avanzado de histología no adenocarcinomatosa. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) SI (Completed) IE (Completed) GB (Completed) BE (Completed) IT (Prematurely Ended) LV (Completed) FR (Completed) BG (Completed) HU (Completed) CZ (Prematurely Ended) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002219-25 | Sponsor Protocol Number: ITCA650-CLP-107 | Start Date*: 2014-09-16 | |||||||||||
Sponsor Name:Intarcia Therapeutics, Inc. | |||||||||||||
Full Title: A Randomized, Multicenter Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for Type 2 Diabetes | |||||||||||||
Medical condition: Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) SK (Completed) EE (Completed) FI (Completed) DE (Completed) DK (Completed) ES (Completed) PL (Completed) BG (Completed) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004476-10 | Sponsor Protocol Number: GEICAM/2011-02 | Start Date*: 2012-01-19 | |||||||||||
Sponsor Name:Fundación Grupo Español de Investigación en Cáncer de Mama (Fundación GEICAM) | |||||||||||||
Full Title: Phase II, open-label, non-randomized study of nab-paclitaxel for the neoadjuvant treatment of patients with stage II and III luminal breast cancer. | |||||||||||||
Medical condition: Neoadjuvant tratment of patients with stage II - III luminal brest cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004167-20 | Sponsor Protocol Number: A1481252 | Start Date*: 2015-03-24 | ||||||||||||||||||||||||||
Sponsor Name:Pfizer Japan Inc | ||||||||||||||||||||||||||||
Full Title: A Phase 3, Multi-Center, Open-Label Study To Confirm Safety, Efficacy And Tolerability Of Sildenafil Citrate 20 Mg Three Times a Day (TID) In Subjects With Pulmonary Arterial Hypertension | ||||||||||||||||||||||||||||
Medical condition: Pulmonary Arterial Hypertension | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-001270-24 | Sponsor Protocol Number: A3671014 | Start Date*: 2007-02-13 | |||||||||||
Sponsor Name:Pfizer Pharma GmbH | |||||||||||||
Full Title: Phase 2, single arm study of ticilimumab in patients with refractory metastatic adenocarcinoma of the colon or rectum | |||||||||||||
Medical condition: Refractory meatstatic adenocarcinoma of the colon or rectum | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
